Professor Stephen Clarke
People_

Professor Stephen Clarke

OAM
Professor of Medicine
Medicine, Northern Clinical School
Kolling Institute of Medical Research
Phone
+61 2 9926 5048 / 7494
Fax
+61 2 9767 7603

Cancer pharmacology, colorectal cancer, lung cancer

Cancer

Publications

Book Chapters

  • Diakos, C., Charles (nee Slaviero), K., Chua, W., Howell, V., Clarke, S. (2015). Biomarkers in Metastatic Colorectal Cancer. In Victor R. Preedy and Vinood B. Patel (Eds.), Biomarkers in Cancer, (pp. 601-629). Dordrecht: Springer. [More Information]
  • McLachlan, A., Clarke, S. (2015). Phytotherapies: Drug Interactions in Cancer. In Not known (Eds.), Phytotherapies: Efficacy, Safety, and Regulation, (pp. 536-553). TBC. [More Information]
  • Clarke, S., McLachlan, A. (2012). Interaction Between Complementary and Alternative Medicines and Conventional Medicines. In Olver, I and Robotin, M (Eds.), Perspectives on Complementary and Alternative Medicines, (pp. 227-259). London: Imperial College Press. [More Information]

Journals

  • Tan, L., Brown, C., Mersiades, T., Lee, C., John, T., Kao, S., Newnham, G., O'Byrne, K., Parakh, S., Bray, V., Yip, S., Clarke, S., Pavlakis, N., Stockler, M., et al (2024). A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE. Nature Communications, 15(1). [More Information]
  • Thomsen, M., Vemuri, R., Huygens, F., Clarke, S., Vitetta, L. (2024). An exploratory study of a multi-species probiotic formulation and markers of health in a real-world oncological cohort in the time of covid. Inflammopharmacology. [More Information]
  • Brown, L., Khou, V., Brown, C., Alexander, M., Jayamanne, D., Wei, J., Gray, L., Chan, W., Smith, S., Harden, S., Mersiades, T., Itchins, M., Pavlakis, N., Clarke, S., Boyer, M., Nagrial, A., Hau, E., Esteves Domingues Pires da Silva, I., Kao, S., Kong, B., et al (2024). First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study. Frontiers in Oncology, 14. [More Information]

Conferences

  • Johnson, S., Butow, P., Bell, M., Detering, K., Clayton, J., Silvester, W., Kiely, B., Clarke, S., Vaccaro, L., Stockler, M., Beale, P., Fitzgerald, N., Tattersall, M. (2017). A Randomized Controlled Trial of an Advance Care Planning Intervention for Patients with Incurable Cancer. The 44th Clinical Oncological Society of Australia Annual Scientific Meeting,.
  • Vaccaro, L., Johnson, S., Kiely, B., Clayton, J., Clarke, S., Beale, P., Silvester, W., Detering, K., Butow, P., Tattersall, M. (2016). Acceptability of tailored life-expectancy information in patients with advanced cancer participating in an Australian nurse-led ACP RCT. The 43nd Clinical Oncological Society of Australia Annual Scientific Meeting,.
  • Clarke, S. (2013). A Medical Oncology Approach to Colorectal Cancer. Cancer Nurses Society of Australia Educational Event 2011.

2024

  • Tan, L., Brown, C., Mersiades, T., Lee, C., John, T., Kao, S., Newnham, G., O'Byrne, K., Parakh, S., Bray, V., Yip, S., Clarke, S., Pavlakis, N., Stockler, M., et al (2024). A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE. Nature Communications, 15(1). [More Information]
  • Thomsen, M., Vemuri, R., Huygens, F., Clarke, S., Vitetta, L. (2024). An exploratory study of a multi-species probiotic formulation and markers of health in a real-world oncological cohort in the time of covid. Inflammopharmacology. [More Information]
  • Brown, L., Khou, V., Brown, C., Alexander, M., Jayamanne, D., Wei, J., Gray, L., Chan, W., Smith, S., Harden, S., Mersiades, T., Itchins, M., Pavlakis, N., Clarke, S., Boyer, M., Nagrial, A., Hau, E., Esteves Domingues Pires da Silva, I., Kao, S., Kong, B., et al (2024). First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study. Frontiers in Oncology, 14. [More Information]

2023

  • Wei, J., Yuile, A., Itchins, M., Kong, B., Li, B., Pavlakis, N., Chan, D., Clarke, S. (2023). Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis. Biomedicines, 11(7). [More Information]
  • Saltz, L., Clarke, S., Diaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T., Rivera, F., et al (2023). Bevacizumab in Combination with Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. Journal of Clinical Oncology, 41(21), 3663-3669. [More Information]
  • Tse, B., Molloy, M., Bergamin, S., Steffen, P., Hruby, G., Pavlakis, N., Clarke, S., Evans, J., Engel, A., Kneebone, A. (2023). CD11c+ and IRF8+ cell densities in rectal cancer biopsies predict outcomes of neoadjuvant chemoradiotherapy. OncoImmunology, 12(1), 2238506. [More Information]

2022

  • Itchins, M., Ainsworth, H., Alexander, M., Dean, S., Dharmaraj, D., Pavlakis, N., Clarke, S., Brown, C., Torres, J., Saqib, A., Kao, S., et al (2022). A Multi-Center Real-World Experience of IMpower150 in Oncogene Driven Tumors and CNS Metastases. Clinical Lung Cancer, 23(8), 702-708. [More Information]
  • Siu, D., Ali, A., Tjokrowidjaja, A., De Silva, M., Lee, J., Clingan, P., Aghmesheh, M., Brungs, D., Mapagu, C., Goldstein, D., Sjoquist, K., Pavlakis, N., Clarke, S., Diakos, C., et al (2022). Clinical and molecular profile of young adults with early-onset colorectal cancer: Experience from four Australian tertiary centers. Asia-Pacific Journal of Clinical Oncology, 18(6), 660-668. [More Information]
  • Chan, D., Clarke, S., Engel, A., Diakos, C., Pavlakis, N., Roach, P., Bailey, D., Bauer, J., Findlay, M. (2022). Computed tomography (CT)-defined sarcopenia and myosteatosis are prevalent in patients with neuroendocrine neoplasms (NENs) treated with peptide receptor radionuclide therapy (PRRT). European Journal of Clinical Nutrition, 76(1), 143-149. [More Information]

2021

  • Lubel, J., Roberts, S., Strasser, S., Thompson, A., Philip, J., Goodwin, M., Clarke, S., Crawford, D., Levy, M., Shackel, N. (2021). Australian recommendations for the management of hepatocellular carcinoma: a consensus statement. Medical Journal of Australia, 214(10), 475-483. [More Information]
  • Mondaca, S., Lebow, E., Namakydoust, A., Razavi, P., Reis-Filho, J., Shen, R., Offin, M., Tu, H., Murciano-Goroff, Y., Xu, C., Pavlakis, N., Clarke, S., Itchins, M., Lee, A., et al (2021). Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. Lung Cancer, 159, 66-73. [More Information]
  • Leal, J., Alexander, M., Itchins, M., Wright, G., Kao, S., Hughes, B., Pavlakis, N., Clarke, S., Gill, A., Ainsworth, H., et al (2021). EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non–Small Cell Lung Cancer: EGFR Exon 20 Insertion Mutations in NSCLC. Clinical Lung Cancer, 22(6), e859-e869. [More Information]

2020

  • Alexander, M., Pavlakis, N., John, T., O'Connell, R., Kao, S., Hughes, B., Lee, A., Hayes, S., Howell, V., Clarke, S., Itchins, M., et al (2020). A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer. Lung Cancer, 142, 34-40. [More Information]
  • Itchins, M., Lau, B., Hudson, A., Westman, H., Xia, C., Hayes, S., Howell, V., Rodriguez, M., Cooper, W., Wei, G., Buckland, M., Li, B., Gill, A., Clarke, S., Pavlakis, N., et al (2020). ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling. The Oncologist, 25(8), 641-649. [More Information]
  • Sagnella, S., Yang, L., Stubbs, G., Boslem, E., Martino-Echarri, E., Smolarczyk, K., Pattison, S., Vanegas, N., St. Clair, E., Clarke, S., et al (2020). Cyto-Immuno-Therapy for Cancer: A Pathway Elicited by Tumor-Targeted, Cytotoxic Drug-Packaged Bacterially Derived Nanocells. Cancer Cell, 37(3), 354-3.70. [More Information]

2019

  • Sabari, J., Offin, M., Stephens, D., Ni, A., Lee, A., Pavlakis, N., Clarke, S., Diakos, C., Datta, S., Tandon, N., et al (2019). A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. Journal of the National Cancer Institute, 111(6), 1-9. [More Information]
  • Lai, W., Lebas, L., Barnes, T., Milia, J., Gautschi, O., Ni, A., Peters, S., Ferrara, R., Plodkowski, A., Kavanagh, J., Clarke, S., Pavlakis, N., et al (2019). Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. European Journal of Cancer, 109, 28-35. [More Information]
  • Trousil, S., Lee, P., Edwards, R., Maslen, L., Lozan‐Kuehne, J., Ramaswami, R., Aboagye, E., Clarke, S., Liddle, C., Sharma, R. (2019). Altered cytochrome 2E1 and 3A P450-dependent drug metabolism in advanced ovarian cancer correlates to tumour-associated inflammation. British Journal of Pharmacology, 176(18), 3712-3722. [More Information]

2018

  • Vafaee, F., Diakos, C., Kirschner, M., Reid, G., Michael, M., Horvath, L., Alinejad-Rokny, H., Cheng, Z., Kuncic, Z., Clarke, S. (2018). A data-driven, knowledge-based approach to biomarker discovery: application to circulating microRNA markers of colorectal cancer prognosis. Npj Systems Biology And Applications, 4, 20. [More Information]
  • Chan, J., Diakos, C., Chan, D., Engel, A., Pavlakis, N., Gill, A., Clarke, S. (2018). A Longitudinal Investigation of Inflammatory Markers in Colorectal Cancer Patients Perioperatively Demonstrates Benefit in Serial Remeasurement. Annals of Surgery, 267(6), 1119-1125. [More Information]
  • Johnson, S., Butow, P., Bell, M., Detering, K., Clayton, J., Silvester, W., Kiely, B., Clarke, S., Vaccaro, L., Stockler, M., Tattersall, M., et al (2018). A randomised controlled trial of an advance care planning intervention for patients with incurable cancer. British Journal of Cancer, 119(10), 1182-1190. [More Information]

2017

  • Johnson, S., Butow, P., Bell, M., Detering, K., Clayton, J., Silvester, W., Kiely, B., Clarke, S., Vaccaro, L., Stockler, M., Beale, P., Fitzgerald, N., Tattersall, M. (2017). A Randomized Controlled Trial of an Advance Care Planning Intervention for Patients with Incurable Cancer. The 44th Clinical Oncological Society of Australia Annual Scientific Meeting,.
  • John, T., Bowden, J., Clarke, S., Fox, S., Garrett, K., Horwood, K., Karapetis, C. (2017). Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer. Asia-Pacific Journal of Clinical Oncology, 13(4), 296-303. [More Information]
  • Shinko, D., Diakos, C., Clarke, S., Charles (nee Slaviero), K. (2017). Cancer-Related Systemic Inflammation: The Challenges and Therapeutic Opportunities for Personalized Medicine. Clinical Pharmacology & Therapeutics, 102(4), 599-610. [More Information]

2016

  • Kao, S., Kirschner, M., Cooper, W., Tran, T., Burgers, S., Wright, C., Korse, T., van den Broek, D., Edelman, J., Vallely, M., McCaughan, B., Pavlakis, N., Clarke, S., van Zandwijk, N., Reid, G., et al (2016). A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma. British Journal of Cancer, 114(5), 524-531. [More Information]
  • Vaccaro, L., Johnson, S., Kiely, B., Clayton, J., Clarke, S., Beale, P., Silvester, W., Detering, K., Butow, P., Tattersall, M. (2016). Acceptability of tailored life-expectancy information in patients with advanced cancer participating in an Australian nurse-led ACP RCT. The 43nd Clinical Oncological Society of Australia Annual Scientific Meeting,.
  • Johnson, S., Clayton, J., Butow, P., Silvester, W., Detering, K., Hall, J., Kiely, B., Cebon, J., Clarke, S., Bell, M., Stockler, M., Tattersall, M., et al (2016). Advance care planning in patients with incurable cancer: Study protocol for a randomised controlled trial. BMJ Open, 6(12), 1-10. [More Information]

2015

  • Kao, S., Fulham, M., Wong, K., Cooper, W., Brahmbhatt, H., MacDiarmid, J., Pattison, S., Sagong, J., Huynh, Y., Leslie, F., Pavlakis, N., Clarke, S., Boyer, M., Reid, G., van Zandwijk, N. (2015). A significant metabolic and radiological response after a novel targeted microRNA-based treatment approach in malignant pleural mesothelioma. American Journal of Respiratory and Critical Care Medicine, 191(12), 1467-1469. [More Information]
  • Furtado, R., Ha, L., Clarke, S., Sandroussi, C. (2015). Adjuvant Iodine (131) Lipiodol after Resection of Hepatocellular Carcinoma. Journal of Oncology, 2015, 1-7. [More Information]
  • Diakos, C., Charles (nee Slaviero), K., Chua, W., Howell, V., Clarke, S. (2015). Biomarkers in Metastatic Colorectal Cancer. In Victor R. Preedy and Vinood B. Patel (Eds.), Biomarkers in Cancer, (pp. 601-629). Dordrecht: Springer. [More Information]

2014

  • Wang, F., Gill, A., Neale, M., Puttaswamy, V., Gananadha, S., Pavlakis, N., Clarke, S., Hugh, T., Samra, J. (2014). Adverse tumor biology associated with mesenterico-portal vein resection influences survival in patients with pancreatic ductal adenocarcinoma. Annals of Surgical Oncology, 21(6), 1937-1947. [More Information]
  • Davis, E., Oh, B., Butow, P., Mullan, B., Clarke, S. (2014). Cancer patient disclosure and patient-doctor communication of complementary and alternative medicine use: A systematic review. Forschende Komplementarmedizin, 21(1), 58-59. [More Information]
  • Diakos, C., Charles (nee Slaviero), K., McMillan, D., Clarke, S. (2014). Cancer-related inflammation and treatment effectiveness. The Lancet Oncology, 15(11), e493-e503. [More Information]

2013

  • Clarke, S. (2013). A Medical Oncology Approach to Colorectal Cancer. Cancer Nurses Society of Australia Educational Event 2011.
  • Hibbert, E., Lambert, T., Carter, J., Learoyd, D., Twigg, S., Clarke, S. (2013). A randomized controlled pilot trial comparing the impact of access to clinical endocrinology video demonstrations with access to usual revision resources on medical student performance of clinical endocrinology skills. BMC Medical Education, 13(1), 1-10. [More Information]
  • Clarke, S., Burge, M., Cordwell, C., Gibbs, P., Reece, W., Tebbutt, N. (2013). An Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (AvastinTM) [ASCENT]. BMC Cancer, 13, 1-7. [More Information]

2012

  • Oh, B., Butow, P., Mullan, B., Hale, A., Lee, M., Guo, X., Clarke, S. (2012). A Critical Review of the Effects of Medical Qigong on Quality of Life, Immune Function, and Survival in Cancer Patients. Integrative Cancer Therapies, 11(2), 101-110. [More Information]
  • Proctor, M., McMillan, D., Morrison, D., Fletcher, C., Horgan, P., Clarke, S. (2012). A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. British Journal of Cancer, 107(4), 695-699. [More Information]
  • Michael, M., Pavlakis, N., Clingan, P., de Boer, R., Johnston, M., Clarke, S. (2012). A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer. Oncology Reports, 28(3), 763-767. [More Information]

2011

  • Kao, S., Yan, T., Lee, K., Burn, J., Henderson, D., Klebe, S., Kennedy, C., Vardy, J., Clarke, S., Van Zandwijk, N., et al (2011). Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma. Journal of Thoracic Oncology, 6(3), 602-605. [More Information]
  • Phan, V., Tan, C., Rittau, A., Xu, H., McLachlan, A., Clarke, S. (2011). An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs. Expert Opinion on Drug Metabolism and Toxicology, 7(11), 1395-1410. [More Information]
  • Clarke, S. (2011). Bone Metastases. Nuclear Medicine Society NSW Educational Meeting.

2010

  • Blinman, P., Duric, V., Nowak, A., Beale, P., Clarke, S., Briscoe, K., Boyce, A., Goldstein, D., Hudson, M., Stockler, M. (2010). Adjuvant chemotherapy for early colon cancer: What survival benefits make it worthwhile? European Journal of Cancer, 46(10), 1800-1807. [More Information]
  • Clarke, S., McLachlan, A., Brown, D., Carbonara, S., Kissane, R. (2010). Beyond Conventional Cancer Treatments: The Use of Complementary Therapies During Cancer Treatment: Implications for Clinicians. In Monica Robotin, Ian Olver, Afaf Girgis (Eds.), When Cancer Crosses Disciplines: A Physicians Handbook, (pp. 285-315). London: Imperial College Press. [More Information]
  • Chua, W., Clarke, S. (2010). Clinical Trial Information As a Measure of Quality Cancer Care. Journal of Oncology Practice, 6(3), 170-171. [More Information]

2009

  • Matic, M., Nakhel, S., Lehnert, A., Polly, P., Clarke, S., Robertson, G. (2009). A novel approach to investigate the subcellular distribution of nuclear receptors in vivo. Nuclear Receptor Signaling, 7, 1-7. [More Information]
  • Chapuis, P., Bokey, E., Clarke, S., Beale, P., Dent, O. (2009). Adjuvant chemotherapy for stage C colonic cancer in a multidisciplinary setting. ANZ Journal of Surgery, 79(10), 685-692. [More Information]
  • Clarke, S. (2009). Advanced colorectal cancer - where are we going? AstraZeneca Challenges in Gastroenterology Symposium.

2008

  • Van Cutsem, E., Verslype, C., Beale, P., Clarke, S., Bugat, R., Rakhit, A., Fettner, S., Brennscheidt, U., Feyereislova, A., Delord, J. (2008). A phase lb dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients. Annals of Oncology, 19(2), 332-339. [More Information]
  • Saltz, L., Clarke, S., Diaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T., Rivera, F., et al (2008). Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. Journal of Clinical Oncology, 26(12), 2013-2019. [More Information]
  • Read, J., Clarke, S. (2008). Clinical Nutrition. In E. Bruera, I. Higginson, C. Ripamonti, C. von Gunten (Eds.), Palliative Medicine, (pp. 595-601). United Kingdom: Hodder Arnold. [More Information]

2007

  • Yeo, W., Boyer, M., Chung, H., Ong, S., Lim, R., Zee, B., Ma, B., Lam, K., Mo, F., Ng, E., Clarke, S., Beale, P., et al (2007). Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG). Cancer Chemotherapy and Pharmacology, 59(3), 295-300. [More Information]
  • Clarke, S., Goldstein, D., Mitchell, P., Michael, M., Beale, P., Friedlander, M., Zalcberg, J., White, S. (2007). Modification of Leucovorin Dose Within a Simplified FOLFOX Regimen Improves Tolerability Without Compromising Efficacy. Clinical Colorectal Cancer, 6(8), 578-582. [More Information]
  • Chuah, B., Lim, R., Boyer, M., Ong, A., Wong, S., Kong, H., Millward, M., Clarke, S., Goh, B. (2007). Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta Oncologica, 46(2), 234-238. [More Information]

2006

  • Sharma, R., Rivory, L., Beale, P., Ong, S., Horvath, L., Clarke, S. (2006). A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. British Journal of Cancer, 94(7), 964-968. [More Information]
  • Tobin, P., Beale, P., Noney, L., Liddell, S., Rivory, L., Clarke, S. (2006). A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 57(3), 309-316. [More Information]
  • Mitchell, P., Goldstein, D., Michael, M., Beale, P., Friedlander, M., Zalcberg, J., White, S., Thomson, J., Clarke, S. (2006). Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clinical Colorectal Cancer, 6(2), 146-151. [More Information]

2005

  • Clarke, S., Boyer, M., Millward, M., Underhill, C., Moylan, E., Yip, D., White, S., Childs, A., Beale, P., Latz, J., et al (2005). A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Lung Cancer, 49(3), 401-412. [More Information]
  • Goldstein, D., Mitchell, P., Michael, M., Beale, P., Friedlander, M., Zalcberg, J., White, S., Clarke, S. (2005). Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients. British Journal of Cancer, 92(5), 832-837. [More Information]
  • Sharpe, L., Butow, P., Smith, C., McConnell, D., Clarke, S. (2005). Changes in quality of life in patients with advanced cancer - Evidence of response shift and response restriction. Journal of Psychosomatic Research, 58(6), 497-504. [More Information]

2004

  • Baker, S., Van Schaik, R., Rivory, L., Ten Tije, A., Dinh, K., Graveland, W., Schenk, P., Charles, J., Clarke, S., Carducci, M., Sparreboom, A., et al (2004). Factors Affecting Cytochrome P-450 3A Activity In Cancer Patients. Clinical Cancer Research, 10(12), 8341-8350. [More Information]
  • Tobin, P., Rivory, L., Clarke, S. (2004). Inhibition of acetylcholinesterase in patients receiving irinotecan (camptothecin-11). Pharmacology and Therapeutics, 76(5), 505-506. [More Information]
  • Vardy, J., Engelhardt, K., Cox, K., Jacquet, J., McDade, A., Boyer, M., Beale, P., Clarke, S., Stockler, M., Loneragan, R., Waugh, R., Clarke, S. (2004). Long-Term Outcome Of Radiological-Guided Insertion Of Implanted Central Venous Access Port Devices (Cvapd) For The Delivery Of Chemotherapy In Cancer Patients: Institutional Experience And Review Of The Literature. British Journal of Cancer, 91(6), 1045-1049. [More Information]

2003

  • Smit, E., Mattson, K., von Pawel, J., Manegold, C., Clarke, S., Postmus, P. (2003). ALIMTA® (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Annals of Oncology, 14(3), 455-460. [More Information]
  • Clarke, S. (2003). An 85-year old woman with metastatic liver disease: clinical case review. Medicine Today, 4(1), 72-73.
  • Charles (nee Slaviero), K., Read, J., Clarke, S., Rivory, L. (2003). Baseline Nutritional Assessment in Advanced Cancer Patients Receiving Palliative Chemotherapy. Nutrition and Cancer, 46(2), 148-157. [More Information]

2002

  • Aristides, M., Chen, J., Schulz, M., Williamson, E., Clarke, S., Grant, K. (2002). Conjoint analysis of a new chemotherapy: willingness to pay and preference for the features of raltitrexed versus standard therapy in advanced colorectal cancer. PharmacoEconomics, 20(11), 775-784. [More Information]
  • Cunningham, D., Zalcberg, J., Maroun, J., James, R., Clarke, S., Maughan, T., Vincent, M., Schulz, J., Gonzalez Baron, M., Facchini, T. (2002). Efficacy, tolerability and management of raltitrexed (Tomudex TM) monotherapy in patients with advanced colorectal cancer: a review of phase II/III trials. European Journal of Cancer, 38(4), 478-486. [More Information]
  • Rivory, L., Charles (nee Slaviero), K., Clarke, S. (2002). Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. British Journal of Cancer, 87(3), 277-280. [More Information]

2001

  • Rivory, L., Clarke, S., Boyer, M., Bishop, J. (2001). Highly sensitive analysis of the antifolate pemetrexed sodium, a new cancer agent, in human plasma and urine by high-performance liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 765, 135-140.
  • Rivory, L., Charles (nee Slaviero), K., Hoskins, J., Clarke, S. (2001). The erythromycin breath test for the prediction of drug clearance. Clinical Pharmacokinetics, 40, 151-158. [More Information]
  • Clarke, S., Bishop, J., Dodds, H., Rivory, L., Ong,, S. (2001). Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction. Anti-Cancer Drugs, 12, 619-625. [More Information]

2000

  • Clarke, S., Beale, P., Rivory, L. (2000). Clinical and preclinical pharmacokinetics of raltitrexed. Clinical Pharmacokinetics, 39, 429-443. [More Information]

Selected Grants

2019

  • Identification of plasma extracellular vesicles signatures in lung cancer patients with brain metastases versus those without, Grau G, Kao S, Hosseini Beheshti E, Clarke S, University of Sydney/Sydney Catalyst
  • Oxtox: Can Oxaliplatin dose reduction and neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer - a phase II randomised study, Vardy J, Dhillon H, Stockler M, Clarke S, Australasian Gastro-Intestinal Trials Group/Research Support

2017

  • Identification of diagnostic protein biomarkers for less invasive screening of lung cancer, Hayes S, Howell V, Pavlakis N, Molloy M, Clarke S, Tour de Cure Ltd/Scott Canner Young Research Grant